FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913809318> ?p ?o ?g. }

• W2913809318 endingPage "91" @default.
• W2913809318 startingPage "79" @default.
• W2913809318 abstract "The aim of this study was to investigate long-term clinical outcomes of extended treatment with CT-P10, a rituximab biosimilar, compared with rituximab reference products sourced from the USA and the EU (US-RTX and EU-RTX) in rheumatoid arthritis (RA) for up to 48 weeks.In this multinational, randomized, double-blind trial, adults with active RA received up to two courses of CT-P10, US-RTX, or EU-RTX alongside methotrexate. Efficacy endpoints included Disease Activity Score 28-joint count (DAS28) and American College of Rheumatology (ACR) response rates. Pharmacokinetics, pharmacodynamics, immunogenicity, and safety were also assessed.Of 372 patients randomized to the study drug, 330 (88.7%) completed the second treatment course. Mean change from baseline to week 48 in DAS28-C-reactive protein was comparable in the CT-P10 and combined rituximab (US-RTX and EU-RTX) groups (- 2.7 and - 2.6, respectively). ACR20, ACR50, and ACR70 response rates at week 48 indicated no differences between groups (80.6%, 55.4%, and 31.7% vs. 79.8%, 53.9%, and 33.7% in the CT-P10 and combined rituximab groups, respectively). Similar improvements in the Health Assessment Questionnaire Disability Index and all medical outcomes in the Short Form 36-Item Health Survey, including physical and mental health, were seen in all groups. At week 48, antidrug antibodies were detected in 4.9%, 9.4%, and 8.6% of patients in the CT-P10, US-RTX, and EU-RTX groups, respectively. CT-P10 and rituximab displayed similar pharmacokinetic, pharmacodynamic, and safety profiles.CT-P10 was similar to EU-RTX and US-RTX in terms of efficacy, pharmacokinetics, pharmacodynamics, immunogenicity, and safety up to week 48. CLINICALTRIALS.NCT02149121." @default.
• W2913809318 created "2019-02-21" @default.
• W2913809318 creator A5004670805 @default.
• W2913809318 creator A5007364793 @default.
• W2913809318 creator A5017006258 @default.
• W2913809318 creator A5023958759 @default.
• W2913809318 creator A5024630591 @default.
• W2913809318 creator A5024934467 @default.
• W2913809318 creator A5032940273 @default.
• W2913809318 creator A5034521486 @default.
• W2913809318 creator A5036530922 @default.
• W2913809318 creator A5040962364 @default.
• W2913809318 creator A5043732079 @default.
• W2913809318 creator A5044949180 @default.
• W2913809318 creator A5045182020 @default.
• W2913809318 creator A5045911413 @default.
• W2913809318 creator A5052206707 @default.
• W2913809318 creator A5063674909 @default.
• W2913809318 creator A5064707258 @default.
• W2913809318 creator A5066408904 @default.
• W2913809318 creator A5071549972 @default.
• W2913809318 creator A5072419462 @default.
• W2913809318 creator A5076575654 @default.
• W2913809318 creator A5076995360 @default.
• W2913809318 creator A5078360050 @default.
• W2913809318 creator A5089475662 @default.
• W2913809318 creator A5089561583 @default.
• W2913809318 creator A5090693306 @default.
• W2913809318 date "2019-02-01" @default.
• W2913809318 modified "2023-10-14" @default.
• W2913809318 title "Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial" @default.
• W2913809318 cites W1974096487 @default.
• W2913809318 cites W1991357220 @default.
• W2913809318 cites W2013797706 @default.
• W2913809318 cites W2021252940 @default.
• W2913809318 cites W2024644107 @default.
• W2913809318 cites W2077158310 @default.
• W2913809318 cites W2125843974 @default.
• W2913809318 cites W2140790130 @default.
• W2913809318 cites W2152348310 @default.
• W2913809318 cites W2165459235 @default.
• W2913809318 cites W2519049669 @default.
• W2913809318 cites W2605493496 @default.
• W2913809318 cites W2736281699 @default.
• W2913809318 cites W2802450016 @default.
• W2913809318 cites W2883406108 @default.
• W2913809318 cites W4249063051 @default.
• W2913809318 cites W4295125684 @default.
• W2913809318 cites W4297929256 @default.
• W2913809318 doi "https://doi.org/10.1007/s40259-018-00331-4" @default.
• W2913809318 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6373391" @default.
• W2913809318 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30719632" @default.
• W2913809318 hasPublicationYear "2019" @default.
• W2913809318 type Work @default.
• W2913809318 sameAs 2913809318 @default.
• W2913809318 citedByCount "24" @default.
• W2913809318 countsByYear W29138093182019 @default.
• W2913809318 countsByYear W29138093182020 @default.
• W2913809318 countsByYear W29138093182021 @default.
• W2913809318 countsByYear W29138093182022 @default.
• W2913809318 countsByYear W29138093182023 @default.
• W2913809318 crossrefType "journal-article" @default.
• W2913809318 hasAuthorship W2913809318A5004670805 @default.
• W2913809318 hasAuthorship W2913809318A5007364793 @default.
• W2913809318 hasAuthorship W2913809318A5017006258 @default.
• W2913809318 hasAuthorship W2913809318A5023958759 @default.
• W2913809318 hasAuthorship W2913809318A5024630591 @default.
• W2913809318 hasAuthorship W2913809318A5024934467 @default.
• W2913809318 hasAuthorship W2913809318A5032940273 @default.
• W2913809318 hasAuthorship W2913809318A5034521486 @default.
• W2913809318 hasAuthorship W2913809318A5036530922 @default.
• W2913809318 hasAuthorship W2913809318A5040962364 @default.
• W2913809318 hasAuthorship W2913809318A5043732079 @default.
• W2913809318 hasAuthorship W2913809318A5044949180 @default.
• W2913809318 hasAuthorship W2913809318A5045182020 @default.
• W2913809318 hasAuthorship W2913809318A5045911413 @default.
• W2913809318 hasAuthorship W2913809318A5052206707 @default.
• W2913809318 hasAuthorship W2913809318A5063674909 @default.
• W2913809318 hasAuthorship W2913809318A5064707258 @default.
• W2913809318 hasAuthorship W2913809318A5066408904 @default.
• W2913809318 hasAuthorship W2913809318A5071549972 @default.
• W2913809318 hasAuthorship W2913809318A5072419462 @default.
• W2913809318 hasAuthorship W2913809318A5076575654 @default.
• W2913809318 hasAuthorship W2913809318A5076995360 @default.
• W2913809318 hasAuthorship W2913809318A5078360050 @default.
• W2913809318 hasAuthorship W2913809318A5089475662 @default.
• W2913809318 hasAuthorship W2913809318A5089561583 @default.
• W2913809318 hasAuthorship W2913809318A5090693306 @default.
• W2913809318 hasBestOaLocation W29138093181 @default.
• W2913809318 hasConcept C111113717 @default.
• W2913809318 hasConcept C112705442 @default.
• W2913809318 hasConcept C126322002 @default.
• W2913809318 hasConcept C168563851 @default.
• W2913809318 hasConcept C1862650 @default.
• W2913809318 hasConcept C198451711 @default.
• W2913809318 hasConcept C2777575956 @default.
• W2913809318 hasConcept C2779338263 @default.
• W2913809318 hasConcept C2780653079 @default.

• next